Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats

Anesthesia and Analgesia

Volumn 102, Issue 1, 2006, Pages 225-232

  Pirat, Arash ^a   Zeyneloglu, Pinar ^a   Aldemir, Derya ^a   Yücel, Muammer ^a   Özen, Özlem ^a   Candan, Selim ^a   Arslan, Gülnaz ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; MALONALDEHYDE; OXYGEN RADICAL; PADGEM PROTEIN; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; EXPERIMENTAL MODEL; HISTOPATHOLOGY; INTESTINE ISCHEMIA; LUNG INJURY; LUNG LAVAGE; LUNG WEIGHT; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY; SCORING SYSTEM; SUPERIOR MESENTERIC ARTERY OBSTRUCTION; TISSUE LEVEL;

EID: 29844443400     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000189554.41095.98     Document Type: Article

References (37)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
2. Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. Chest 2001;120:1347-67.
3. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
4. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997;278:313-21.
5. Steinberg D, Gotto Jr. AM. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA 1999;282:2043-50.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
7. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des 2001;7:715-36.
8. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003;2:332-8.
9. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002;23:482-6.
10. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10:543-59.
11. Yildirir A, Muderrisoglu H. Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol 2004;2:309-18.
12. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21.
13. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194-9.
14. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:58-63.
15. Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003;31:S195-9.
16. Strieter RM, Kunkel SL, Keane MP, Standiford TJ. Chemokines in lung injury: Thomas A. Neff Lecture. Chest 1999;116:103S-10S.
17. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978:52:302-10.
18. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
19. Van Aelst L, D'Souza-Schorey C, Rho GT. Pases and signaling networks. Genes Dev 1997;11:2295-322.
20. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23:729-36.
21. Jones GE. Cellular signaling in macrophage migration and chemotaxis. J Leukoc Biol 2000;68:593-o02.
22. Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001;21:1327-32.
23. Liu L, Moesner P, Kovach NL, et al. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem 1999;274:33334-40.
24. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-75.
25. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540-56.
26. Mulhaupt F, Matter CM, Kwak BR, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003;59:755-66.
27. Naidu BV, Woolley SM, Farivar AS, et al. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 2003;126:482-9.
28. Joyce M, Kelly CJ, Chen G, Bouchier-Hayes DJ. Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase. Eur J Vasc Endovasc Surg 2001;21:295-300.
29. Fuhrman B, Koren L, Volkova N, et al. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002;164:179-85.
30. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003;108:1567-74.
31. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
32. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction-modulation by statins. Endothelium 2003;10:23-33.
33. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem 1996;271:13422-9.
34. Chang DM, Hsu K, Ding YA, Chiang CH. Interleukin-1 in ischemia-reperfusion acute lung injury. Am J Respir Crit Care Med 1997;156:1230-4.
35. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999;147:253-61.
36. Orfanos SE, Mavrommati I, Korovesi I, Roussos C. Pulmonary endothelium in acute lung injury: from basic science to the critically ill. Intensive Care Med 2004;30:1702-14.
37. Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2005;288:L3-15.